Document Detail

Peripheral thrombolysis with tissue plasminogen activator. Results of two treatment regimens.
MedLine Citation:
PMID:  8048859     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The purpose of this study was to document the response to tissue plasminogen activator given as either a low-dose intra-arterial infusion or a bolus infusion in patients with peripheral arterial or bypass graft occlusion. DESIGN: Fifty thrombolytic procedures were carried out in 45 patients with a recent occlusion of a peripheral artery (41) or bypass graft (nine). A continuous infusion of 1.0 mg/h of tissue plasminogen activator was used in 27 patients (group A), while 23 patients were given a 20-mg bolus followed by an infusion of 1.0 mg/h (group B). Patients in the two groups were followed up for 12.1 +/- 9.3 months and 11.1 +/- 9.1 months, respectively. RESULTS: In group A, the angiographic lysis rate was 74% and clinical success rate was 67%. In group B, the comparable rates were 70% and 48%. Lysis was quicker when a bolus infusion was used, the mean lysis time being 14.4 +/- 7.9 hours compared with 26.7 +/- 9.4 hours following infusion alone (P = .0005). There was one instance of major hemorrhage in group A and eight in group B (P = .0022), including two patients with cerebral hemorrhage, one of whom died. CONCLUSION: Low-dose tissue plasminogen activator infusion is safe and reasonably effective, although a long treatment time is required. A bolus infusion regimen speeds lysis but is attended by a high incidence of serious hemorrhage.
A S Ward; S K Andaz; S Bygrave
Related Documents :
24384649 - Treating lacunar strokes occurring on aspirin: adding clopidogrel is not the simple sol...
24485959 - Use of argatroban: experiences in continuous renal replacement therapy in critically il...
19394549 - Midterm results of a precuffed expanded polytetrafluoroethylene graft for above knee fe...
24532639 - Does repeat thymectomy improve symptoms in patients with refractory myasthenia gravis?
24247169 - Congenital hypothyroidism treatment in infants: a comparative study between liquid and ...
22955159 - Toxic epidermal necrolysis: performance of scorten and the score-based comparison of th...
1488569 - Cardiorespiratory function in surgically treated thoracic scoliosis with respect to deg...
9559429 - Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acu...
8951759 - Does cervical spinal cord injury induce a higher incidence of complications after proph...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Archives of surgery (Chicago, Ill. : 1960)     Volume:  129     ISSN:  0004-0010     ISO Abbreviation:  Arch Surg     Publication Date:  1994 Aug 
Date Detail:
Created Date:  1994-08-30     Completed Date:  1994-08-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9716528     Medline TA:  Arch Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  861-5     Citation Subset:  AIM; IM    
Department of Surgery, District Hospital, Basingstoke, England.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Graft Occlusion, Vascular / drug therapy*
Infusions, Intra-Arterial
Middle Aged
Peripheral Vascular Diseases / drug therapy*
Thrombolytic Therapy / adverse effects,  methods*
Tissue Plasminogen Activator / administration & dosage,  therapeutic use*
Reg. No./Substance:
EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of a novel 21-aminosteroid or methylprednisolone in experimental total intestinal ischemia.
Next Document:  Outcome of ileorectal anastomosis in an inflammatory bowel disease surgery experience of three decad...